Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solifenacin and mirabegron combination therapy for overactive bladder
NL-OMON41698Phase 3Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Jan 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of solifenacin and mirabegron in overactive bladder (OAB) (5 arms), sponsored by Astellas Pharma. Primary endpoints: Change from baseline in mean number of incontinence episodes per 24 hours at end of treatment and Change from baseline in mean number of micturitions per 24 hours at end of treatment. Started Jan 2014; status: active, not recruiting.
02
Drugs
solifenacinmirabegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NL-OMON41698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41698.